Advances in clinical research on stem cell therapy for sepsis
10.16352/j.issn.1001-6325.2025.09.1234
- VernacularTitle:干细胞治疗脓毒症的临床研究进展
- Author:
Xinyu NIU
1
;
Zhiming SUN
;
Min XIE
;
Shuangling LI
Author Information
1. 北京大学第一医院 重症医学科,北京 100034
- Keywords:
sepsis;
stem-cell;
acute respiratory distress syndrome;
acute kidney injury;
sepsis associated myopathy
- From:
Basic & Clinical Medicine
2025;45(9):1234-1238
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis is a life-threatening acute organ dysfunction syndrome caused by a dys-regulated host response to infection.As a regenerative medicine therapy with broad clinical prospects,stem cells have attracted significant at-tention due to their multifaceted biological capabilities,including anti-inflammatory,antioxidant,and anti-apoptotic effects,as well as immunomodulatory properties and tissue/organ repair potential.Mesenchymal stem cells(MSCs)function through mechanisms such as modulating macrophage polarization and suppressing excessive inflammation responses,thereby promoting tissue regeneration.Pre-clinical studies demonstrate that MSCs significantly reduce sepsis mortality and decrease sepsis-associated complications including acute kidney injury(AKI),acute respiratory distress syndrome(ARDS)and sepsis associated myopathy.Furthermore,perinatal-derived stem cells and genetically modified stem cells have shown therapeutic promise in sepsis management.Current challenges in stem cell-based sepsis therapy cover optimizing delivery strategies,standardizing cell preparation protocols and de-veloping biomarker-guided personalized therapeutic regimens.
